Lipid-lowering drugs, particularly statins, are reviewed for their potential protective role in reducing breast cancer incidence and mitigating treatment-induced cardiotoxicity.
Do lipid-lowering drugs reduce the incidence of breast cancer and mitigate treatment-induced cardiotoxicity in breast cancer patients?
This review synthesizes current evidence on the potential pleiotropic effects of lipid-lowering drugs, particularly statins, in reducing breast cancer incidence and mitigating anti-cancer treatment-induced cardiotoxicity.
The bidirectional link between cancer and cardiovascular disease presents a growing clinical challenge, often exacerbated by the cardiotoxic effects of many anti-cancer drugs. Simultaneously, the incidence of cardiovascular pathologies in cancer patients is on the rise. Recently, lipid-lowering drugs, particularly statins, have emerged not only as first-line cardiovascular drugs but also as potential agents with pleiotropic effects that could influence cancer progression and mitigate cardiotoxic side effects. We will analyze data from epidemiological studies, clinical trials, and laboratory research. This comprehensive review aims to examine and synthesize the current evidence regarding the use of lipid-lowering drugs in breast cancer patients, focusing on two main areas: their potential protective role in reducing the incidence of breast cancer and their impact on the prevention and management of treatment-induced cardiotoxicity.
Mauriello et al. (2025) conducted a review in Breast cancer and cardiotoxicity. Lipid-lowering drugs (statins) was evaluated. Lipid-lowering drugs, particularly statins, are reviewed for their potential protective role in reducing breast cancer incidence and mitigating treatment-induced cardiotoxicity.